12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIIB037: Phase Ib started

Biogen Idec disclosed in its 3Q12 earnings that during the quarter it began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate multiple doses of IV BIIB037 in about...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >